Overview

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

Status:
Unknown status

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and efficacy of every 2 week intravitreal aflibercept injections in a population of neovascular AMD patients that have demonstrated refractory subretinal fluid with or without intraretinal fluid despite prior monthly intravitreal aflibercept treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Tennessee Retina

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept